Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2916 (LINC02916) is a member of the lincRNA family—RNA genes transcribed from intergenic regions of the genome that do not code for proteins[1][5]. Generally exceeding 200 nucleotides in length, lincRNAs regulate gene expression at the transcriptional, post-transcriptional, and epigenetic levels[4]. Some lincRNAs modulate nearby (cis) or distant (trans) genes and serve as scaffolds for chromatin-modifying complexes, act as molecular sponges for microRNAs, or influence mRNA stability[2][3][4]. While many lincRNAs—including LINC02916—have poorly characterized or unknown biological roles, the class as a whole is increasingly implicated in cancer development and progression through the regulation of cell proliferation, apoptosis, and differentiation[2][3][4]. To date, LINC02916 itself is primarily a genomic locus annotation with scarce direct functional or disease-related data[1][5]. No evidence has established it as a therapeutic target or linked it to drug interactions, patient biomarkers, or specific mechanisms of action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2916 (LINC02916).